跳至主要内容
临床试验/CTRI/2024/04/065851
CTRI/2024/04/065851尚未招募2/3 期

A comparative clinical study of Sarvanga Takradhara and Kushthaghana mahakashaya parisheka after Virechana karma in the management of Mandal Kushtha with special reference to Plaque Psoriasis.

National Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年5月15日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
入组人数
30
试验地点
1
主要终点
Changes in PASI Score at Baseline (Day 0), Day 15, Day 30.

研究概览

简要总结

In Ayurveda, Kushthais described as â€˜Achikitasa’and â€˜Mahagada’.  Although in Ayurveda most of the skin diseases were described under the heading of Kushtha. Kushtha is further classified as ‘Mahakushtha and Kshudrakushtha’. Acharaya Charakamationed that all types of Kushtha are ‘Tridoshaja’ . In ‘Mandal Kushtha’ shows features like ‘Shwetam’ (white patches), ‘Raktam’ (red patch), Sthiram’(stable), ‘Styanam’(glossy), â€˜Singdham’(unctuous), â€˜Annyonasansaktam’(combined or joined patches), â€˜Uttsanmandalam’(elevated above the normal skin layer and circular patches), ‘Kricha’ (difficult to heal). This are important clinical feature of Mandal**Kushtha. This clinical features of *‘Mandal**Kushtha’*are nearly corelated to Plaque Psoriasis.

In modern medicine, Psoriasis is one of the most common dermatological disease, affecting up to 1% of world’s population. It is chronic inflammatory skin disorder. Clinically characterised by erythematous, sharply demarcated papules and round plaques covered by silvery micaceous scale. The etiology of Plaque Psoriasis is still poorly understood, but there is clearly genetic component to the disease. Hence it is non-contagious. Plaque Psoriasis is treated with glucocorticoids (methotrexate), topical vitamin D analogue (calcipotriene) and ultraviolet A and B spectrum with either oral or topical psoralens (PUVA)

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients between 18 to 60 years of age.
  • 2.Patients with the classical features of Mandal Kushtha (Plaque Psoriasis).
  • 3.Patients not taking any other medicine for Mandal Kushtha (Plaque Psoriasis).
  • 4.Patients fit for Virechana Karma.
  • 5.Patients willing to sign consent form for trial.

排除标准

  • 1.Pregnant women and lactating mothers.
  • 2.Patients suffering from systemic disorders as Cardiac Problem, Uncontrolled Diabetes mellitus, Uncontrolled Hypertension, Paralysis, Malignancy, HIV, HBsAg, Leprosy.
  • 3.Patients suffering from Psoriatic Arthritis.
  • 4.Patients unfit for Virechana Karma.

结局指标

主要结局

Changes in PASI Score at Baseline (Day 0), Day 15, Day 30.

时间窗: four weeks

次要结局

  • Changes in ayurvedic parameters at Day 0, Day 15, Day 30.(4 weeks)

研究者

申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Gopesh Mangal

National Institute of Ayurveda Jaipur

研究点 (1)

Loading locations...

相似试验